| Literature DB >> 35497804 |
Jing Miao1, Samih H Nasr2, Ladan Zand1, Andrea G Kattah1.
Abstract
Entities:
Year: 2021 PMID: 35497804 PMCID: PMC9039422 DOI: 10.1016/j.ekir.2021.12.031
Source DB: PubMed Journal: Kidney Int Rep ISSN: 2468-0249
Relevant laboratory data
| Parameters | Results | Reference range | ||
|---|---|---|---|---|
| 1 mo before admission | On admission | 3 or 5 d after admission | ||
| CBC | ||||
| White blood cell count, /μl | 9900 | 10,700 | 8700 | 3400–9600 |
| Hemoglobin, g/dl | 12.2 | 12.3 | 10.6 | 11.6–15.0 |
| Hematocrit, % | 36.6 | 37.5 | 32.8 | 35.5–44.9 |
| Platelet count, /μl | 239,000 | 201,000 | 161,000 | 157,000–371,000 |
| Peripheral smear | Negative | |||
| Chemistry | ||||
| Sodium, mmol/l | 141 | 135 | 139 | 135–145 |
| Potassium, mmol/l | 3.9 | 4.3 | 4 | 3.6–5.2 |
| Chloride, mmol/l | 102 | 99 | 105 | 98–107 |
| Bicarbonate, mmol/l | 22 | 22 | 25 | 22–29 |
| Anion gap, mmol/l | 17 | 14 | 9 | 7–15 |
| BUN, mg/dl | 7 | 11 | 13 | 6–21 |
| Serum creatinine, mg/dl | 0.7 | 1.12 | 1.2 | 0.59–1.04 |
| eGFR, ml/min per 1.73 m2 | 66 | ≥60 | ||
| Serum calcium, mg/dl | 11.2 | 8.5 | 8.6–10.0 | |
| Ionized calcium, mg/dl | 5.57 | 4.4–5.2 | ||
| Glucose, mg/dl | 166 | 119 | 67 | 70–140 |
| Total bilirubin, mg/dl | 0.6 | <1.2 | ||
| Alanine aminotransferase, U/l | 28 | 7–45 | ||
| Aspartate aminotransferase, U/l | 41 | 38 | 8–43 | |
| Alkaline phosphatase, U/l | 220 | 35–104 | ||
| Albumin, g/dl | 2.6 | 2 | 3.5–5.0 | |
| Uric acid, mg/dl | 6.7 | 2.7–6.1 | ||
| Beta-hydroxybutyrate, mmol/l | 1.4 | <0.4 | ||
| Bone mineral metabolism | ||||
| Parathyroid hormone, pg/ml | 12 | 15–65 | ||
| 1,25 dihydroxy D2, pg/ml | 36 | 18–78 | ||
| 25-hydroxy D3, ng/ml | 50 | |||
| Immune serologies | ||||
| Total complement, U/ml | 49 | 30–75 | ||
| Alternative complement path function, % | 34 | ≥46 | ||
| Factor B, mg/dl | 36.4 | 15.2–42.3 | ||
| Factor H, mg/dl | 32.1 | 18.5–40.8 | ||
| C4d, mcg/ml | <1.4 | <9.9 | ||
| CBb, mcg/ml | 1.4 | <1.7 | ||
| SC5b-9, ng/ml | 275 | <251 | ||
| C3, mg/dl | 122 | 75–175 | ||
| C4, mg/dl | 13 | 14–40 | ||
| Infectious workup | ||||
| HBs antigen | Negative | |||
| HCV antibody | Negative | |||
| HIV | Negative | |||
| Blood culture | Negative | Negative | ||
| Coagulation | ||||
| Prothrombin time, s | 8.9 | 9.4–12.5 | ||
| INR | 0.8 | 0.9–1.1 | ||
| Activated partial thromboplastin time, s | 26 | 25–37 | ||
| DRVVT screen ratio | 0.8 | <1.2 | ||
| Urinary analysis | ||||
| pH | 5.0 | 5.0 | 5.0–9.0 | |
| Gravity | >1.035 | >1.035 | 1.001–1.035 | |
| Glucose | ≥1000 | Negative | Negative | |
| Ketone | Trace | Trace | Negative | |
| Bilirubin | Negative | Moderate | Negative | |
| Urobilinogen, mg/dl | 0.2 | 1 | 0.2–1.0 | |
| Blood | Negative | Negative | Negative | |
| Leukocyte esterase | Negative | Small | Negative | |
| Nitrite | Negative | Negative | Negative | |
| RBC, /hpf | 3–10 | 0–2 | ||
| WBC, /hpf | 4–10 | 0–10 | ||
| Casts | Negative | |||
| Epithelial, squamous | 1–3 | |||
| 24-h urine protein, mg | 116 | 106 | ||
| Sodium, mmol/l | <10 | |||
| Calcium, mg/dl | 37 | |||
| Calcium-to-creatine ratio, mg/mg | 0.17 | |||
| Urinary protein-to-creatinine ratio, mg/mg | 0.11 | 0.09 | <0.18 | |
| Urine culture | Negative | Negative | ||
BUN, blood urea nitrogen; CBC, complete blood cell count; DRVVT, diluted Russell viper venom time; eGFR, estimated glomerular filtration rate; HBs, hepatitis B surface; HCV, hepatitis C virus; hpf, high power field; INR, international normalized ratio; RBC, red blood cell; WBC, white blood cell.
Dynamic changes of serum creatinine and calcium levels are found in Figure 1.
Figure 1Time course of serum creatinine, serum calcium, and blood pressure. DBP, diastolic blood pressure; SBP, systolic blood pressure.
Figure 2Kidney biopsy findings. (a) Image of the depicted glomerulus reveals global mesangiolysis, loss of endothelial cells, and global widening of subendothelial zone by entrapped plasma proteins (Jones methenamine silver, ×600). (b) Image of another glomerulus reveals a small intraluminal fibrin thrombus that stains dark red on trichrome stain (arrow) (×600). (c) An electron microscopy image revealing marked endothelial cell swelling leading to marked narrowing of the capillary lumen (capillary on the left). The glomerular capillary on the right exhibits loss of endothelial cells and subendothelial and intraluminal electron-dense deposits (likely representing entrapped IgM and other plasma proteins) (×8000). (d) Image of a glomerular capillary revealing an injured, swollen endothelial cell with loss of fenestrations and intracytoplasmic electron-dense lipid particles and lysosomes (electron microscopy, ×12,000).
Teaching points
| Preeclampsia should be considered in cases of AKI late in pregnancy. |
| Preeclampsia should be suspected in pregnant women with AKI even in the absence of proteinuria and/or persistent blood pressure elevation, particularly if the patient has risk factors for preeclampsia, alternative causes cannot be identified, and the timing in gestation is consistent. |
| Kidney biopsy should be considered for AKI in pregnancy when there is a significant chance it would change therapy and dictate timing of delivery. |
| Delivery is currently the only treatment for preeclampsia, which raises the stakes of making a correct and timely diagnosis. In the absence of reliable and easily accessible biomarkers, kidney biopsy would remain essential for the diagnosis of preeclampsia in certain cases where a decision is needed for immediate treatment. |
AKI, acute kidney injury.